Post-chemoradiotherapy adjuvant chemotherapy of rectal cancer

The aim of review. To present the analysis of available data on approach to pharmacological antineoplastic therapy at rectal cancer (RC) after chemoradiotherapy followed by surgical treatment, as well as within the «watch & wait» concept. Summary. The present time adjuvant chemotherapy is the st...

Full description

Saved in:
Bibliographic Details
Main Authors: E. V. Ledin, A. V. Kochatkov
Format: Article
Language:Russian
Published: Gastro LLC 2018-08-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
Online Access:https://www.gastro-j.ru/jour/article/view/161
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823860289888583680
author E. V. Ledin
A. V. Kochatkov
author_facet E. V. Ledin
A. V. Kochatkov
author_sort E. V. Ledin
collection DOAJ
description The aim of review. To present the analysis of available data on approach to pharmacological antineoplastic therapy at rectal cancer (RC) after chemoradiotherapy followed by surgical treatment, as well as within the «watch & wait» concept. Summary. The present time adjuvant chemotherapy is the standard of treatment for III stage rectal cancer after preoperative chemoradiotherapy and surgery. However according to detailed analysis, in this group of patients adjuvant chemotherapy has inconsistent results and no clear-cut advantage can be found at absence of lymph node involvement according to histological study or complete tumor regression due to preoperative chemoradiotherapy. The meta-analysis (2015) of 4 randomized third-phase clinical trials (EORTC 22921, I-CNR-RT, PROCTORSCRIPT, CHRONICLE) demonstrated the lack of significant of 5-fluorouracil-based adjuvant chemotherapy. Efficacy of 5-fluorouracil monotherapy was directly compared to 5-fluorouracil with oxaliplatin combination in several randomized trials. Results of the studies indicate that patients with stage ypI or complete morphological response obtain no significant advantage from adjuvant chemotherapy. The same conclusion can be drawn concerning patients with postponed or cancelled surgery who received treatment within «watch & wait» program. At meta-analysis of 12 studies implementing «watch & wait» protocol with subsequent chemotherapy no definite advantages of adjuvant chemotherapy were demonstrated as well. On the other hand, 5-fluorouracil and oxaliplatin-based chemotherapy should be recommended to patients with ypIII stage of the disease and II stage patients having risk factors. Conclusion. The decision to prescribe adjuvant chemotherapy seems to be correct in relation to pathologic study results and degree of preoperative chemoradiotherapy response.
format Article
id doaj-art-7385db0bc3be4d22b7c84821b8e4d4d2
institution Kabale University
issn 1382-4376
2658-6673
language Russian
publishDate 2018-08-01
publisher Gastro LLC
record_format Article
series Российский журнал гастроэнтерологии, гепатологии, колопроктологии
spelling doaj-art-7385db0bc3be4d22b7c84821b8e4d4d22025-02-10T16:14:28ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732018-08-01273849210.22416/1382-4376-2017-27-3-84-92161Post-chemoradiotherapy adjuvant chemotherapy of rectal cancerE. V. Ledin0A. V. Kochatkov1Federal state autonomous institution «Treatment and rehabilitation center»Clinical hospital #1, MEDSIThe aim of review. To present the analysis of available data on approach to pharmacological antineoplastic therapy at rectal cancer (RC) after chemoradiotherapy followed by surgical treatment, as well as within the «watch & wait» concept. Summary. The present time adjuvant chemotherapy is the standard of treatment for III stage rectal cancer after preoperative chemoradiotherapy and surgery. However according to detailed analysis, in this group of patients adjuvant chemotherapy has inconsistent results and no clear-cut advantage can be found at absence of lymph node involvement according to histological study or complete tumor regression due to preoperative chemoradiotherapy. The meta-analysis (2015) of 4 randomized third-phase clinical trials (EORTC 22921, I-CNR-RT, PROCTORSCRIPT, CHRONICLE) demonstrated the lack of significant of 5-fluorouracil-based adjuvant chemotherapy. Efficacy of 5-fluorouracil monotherapy was directly compared to 5-fluorouracil with oxaliplatin combination in several randomized trials. Results of the studies indicate that patients with stage ypI or complete morphological response obtain no significant advantage from adjuvant chemotherapy. The same conclusion can be drawn concerning patients with postponed or cancelled surgery who received treatment within «watch & wait» program. At meta-analysis of 12 studies implementing «watch & wait» protocol with subsequent chemotherapy no definite advantages of adjuvant chemotherapy were demonstrated as well. On the other hand, 5-fluorouracil and oxaliplatin-based chemotherapy should be recommended to patients with ypIII stage of the disease and II stage patients having risk factors. Conclusion. The decision to prescribe adjuvant chemotherapy seems to be correct in relation to pathologic study results and degree of preoperative chemoradiotherapy response.https://www.gastro-j.ru/jour/article/view/161рак прямой кишкиадъювантная химиотерапияхимиолучевая терапия
spellingShingle E. V. Ledin
A. V. Kochatkov
Post-chemoradiotherapy adjuvant chemotherapy of rectal cancer
Российский журнал гастроэнтерологии, гепатологии, колопроктологии
рак прямой кишки
адъювантная химиотерапия
химиолучевая терапия
title Post-chemoradiotherapy adjuvant chemotherapy of rectal cancer
title_full Post-chemoradiotherapy adjuvant chemotherapy of rectal cancer
title_fullStr Post-chemoradiotherapy adjuvant chemotherapy of rectal cancer
title_full_unstemmed Post-chemoradiotherapy adjuvant chemotherapy of rectal cancer
title_short Post-chemoradiotherapy adjuvant chemotherapy of rectal cancer
title_sort post chemoradiotherapy adjuvant chemotherapy of rectal cancer
topic рак прямой кишки
адъювантная химиотерапия
химиолучевая терапия
url https://www.gastro-j.ru/jour/article/view/161
work_keys_str_mv AT evledin postchemoradiotherapyadjuvantchemotherapyofrectalcancer
AT avkochatkov postchemoradiotherapyadjuvantchemotherapyofrectalcancer